Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With RAS/BRAF Wild-Type Metastatic Colorectal Cancer: The Phase III TRIPLETE Study by GONO
GastroenterologiaSobre o estudo
- Desenho
- Ensaio clínico randomizado
- Nível de evidência
- 2 · Nova evidência
- Revista
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology
- Publicado em
- 6 jun 2022
- Citações
- 0
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With RAS/BRAF Wild-Type Metastatic Colorectal Cancer: The Phase III TRIPLETE Study by GONO
Daniele Rossini, Carlotta Antoniotti, Sara Lonardi, Filippo Pietrantonio, Roberto Moretto, Lorenzo Antonuzzo, Alessandra Boccaccino, Federica Morano, Marco Brugia, Carmelo Pozzo et al.
Descritores MeSH
- Colorectal Neoplasms
- Colonic Neoplasms
- Rectal Neoplasms
- Antineoplastic Combined Chemotherapy Protocols
- Camptothecin
- Leucovorin
- Fluorouracil
- Humans
- Organoplatinum Compounds
- Prospective Studies
Veja também
Estudos relacionados
- First-Line Systemic Treatment for Initially Unresectable Colorectal Liver Metastases: Post Hoc Analysis of the CAIRO5 Randomized Clinical Trial
- Upfront Modified FOLFOXIRI Plus Panitumumab for RAS/BRAF Wild-Type Metastatic Colorectal Cancer: Final Results of the Phase III TRIPLETE Study
- Intermittent or Continuous Panitumumab Plus Fluorouracil, Leucovorin, and Irinotecan for First-Line Treatment of RAS and BRAF Wild-Type Metastatic Colorectal Cancer: The IMPROVE Trial
- Delta tocotrienol as a supplement to FOLFOXIRI in first-line treatment of metastatic colorectal cancer. A randomized, double-blind, placebo-controlled phase II study